Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) Quarterly Sentiment Report

June 15, 2018 - By Henry Gaston

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Logo

Sentiment for Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)

Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) institutional sentiment decreased to 0.96 in 2018 Q1. Its down -0.65, from 1.61 in 2017Q4. The ratio turned negative, as 44 institutional investors started new or increased positions, while 46 sold and reduced stock positions in Biocryst Pharmaceuticals Inc. The institutional investors in our partner’s database now hold: 85.89 million shares, down from 87.26 million shares in 2017Q4. Also, the number of institutional investors holding Biocryst Pharmaceuticals Inc in their top 10 positions decreased from 2 to 1 for a decrease of 1. Sold All: 20 Reduced: 26 Increased: 26 New Position: 18.

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company has market cap of $559.73 million. The firm markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It currently has negative earnings. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology.

The stock decreased 0.18% or $0.01 during the last trading session, reaching $5.67. About 423,106 shares traded. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has declined 9.66% since June 15, 2017 and is downtrending. It has underperformed by 22.23% the S&P500.

Analysts await BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report earnings on August, 6. They expect $-0.21 earnings per share, 0.00 % or $0.00 from last year’s $-0.21 per share. After $-0.26 actual earnings per share reported by BioCryst Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -19.23 % EPS growth.

Ra Capital Management Llc holds 2.55% of its portfolio in BioCryst Pharmaceuticals, Inc. for 6.98 million shares. Dafna Capital Management Llc owns 974,652 shares or 2.26% of their US portfolio. Moreover, Baker Bros. Advisors Lp has 0.57% invested in the company for 14.01 million shares. The United Kingdom-based Cheyne Capital Management (Uk) Llp has invested 0.22% in the stock. Rock Springs Capital Management Lp, a Maryland-based fund reported 925,000 shares.

Since January 1, 0001, it had 0 buys, and 1 insider sale for $265,306 activity.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Coverage

Ratings analysis reveals 67% of Biocryst Pharmaceuticals’s analysts are positive. Out of 3 Wall Street analysts rating Biocryst Pharmaceuticals, 2 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $6 while the high is $10.0. The stock’s average target of $7.33 is 29.28% above today’s ($5.67) share price. BCRX was included in 4 notes of analysts from December 20, 2017. The firm earned “Buy” rating on Tuesday, January 23 by H.C. Wainwright. The rating was maintained by H.C. Wainwright on Wednesday, May 9 with “Buy”. The rating was upgraded by RBC Capital Markets on Tuesday, January 2 to “Outperform”.

More recent BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) news were published by: which released: “BioCryst Announces Presentation of Additional Analyses of the APeX-1 Clinical Trial of BCX7353 at the 2018 …” on May 29, 2018. Also published the news titled: “BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference” on June 13, 2018.‘s news article titled: “BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference” with publication date: May 24, 2018 was also an interesting one.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.